Clear Trail Advisors LLC Invests $4.29 Million in Medtronic PLC $MDT

Clear Trail Advisors LLC purchased a new position in shares of Medtronic PLC (NYSE:MDT) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 44,612 shares of the medical technology company’s stock, valued at approximately $4,285,000. Medtronic makes up approximately 1.0% of Clear Trail Advisors LLC’s portfolio, making the stock its 29th biggest position.

A number of other large investors have also recently added to or reduced their stakes in the stock. Murphy Middleton Hinkle & Parker Inc. grew its stake in Medtronic by 125.3% in the 4th quarter. Murphy Middleton Hinkle & Parker Inc. now owns 11,963 shares of the medical technology company’s stock valued at $1,149,000 after buying an additional 6,653 shares during the last quarter. SG Americas Securities LLC lifted its position in Medtronic by 2,297.7% during the 4th quarter. SG Americas Securities LLC now owns 2,510,712 shares of the medical technology company’s stock worth $241,179,000 after acquiring an additional 2,406,000 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Medtronic by 2.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 35,292 shares of the medical technology company’s stock valued at $3,390,000 after acquiring an additional 866 shares during the period. Park Place Capital Corp boosted its holdings in Medtronic by 55.7% during the fourth quarter. Park Place Capital Corp now owns 383 shares of the medical technology company’s stock valued at $37,000 after acquiring an additional 137 shares during the period. Finally, Diversified Trust Co. grew its position in shares of Medtronic by 14.8% in the fourth quarter. Diversified Trust Co. now owns 111,179 shares of the medical technology company’s stock valued at $10,680,000 after purchasing an additional 14,304 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on MDT shares. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. Wall Street Zen lowered shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Sunday, March 1st. Daiwa Securities Group reduced their price target on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a report on Friday, February 27th. Needham & Company LLC restated a “buy” rating and issued a $120.00 price target on shares of Medtronic in a research report on Tuesday, March 10th. Finally, Mizuho upgraded shares of Medtronic to a “strong-buy” rating in a report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and an average price target of $110.74.

Medtronic Stock Up 1.3%

MDT opened at $87.24 on Tuesday. The firm has a market cap of $112.01 billion, a price-to-earnings ratio of 24.30, a PEG ratio of 2.21 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The firm’s 50-day simple moving average is $96.63 and its 200-day simple moving average is $96.69. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic’s dividend payout ratio is 79.11%.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.26% of the stock is owned by corporate insiders.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).